Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2025-01-01 DOI:10.1016/j.ygyno.2024.11.010

Rebecca A. Previs , Kyle C. Strickland , Zachary Wallen , Heidi Ko , Michelle Green , Maureen Cooper , Elizabeth Lyon , Michael Biorn , Jennifer Armetta , Rennie Quarles , Catherine H. Watson , Kari Ring , Jonathan L. Klein , Brian Caveney , Eric A. Severson , Shakti Ramkissoon

{"title":"Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers","authors":"Rebecca A. Previs , Kyle C. Strickland , Zachary Wallen , Heidi Ko , Michelle Green , Maureen Cooper , Elizabeth Lyon , Michael Biorn , Jennifer Armetta , Rennie Quarles , Catherine H. Watson , Kari Ring , Jonathan L. Klein , Brian Caveney , Eric A. Severson , Shakti Ramkissoon","doi":"10.1016/j.ygyno.2024.11.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Epithelial ovarian cancer (EOC) remains a significant challenge in gynecologic oncology, particularly in the context of platinum-resistant disease. Mirvetuximab soravtansine (MIRV), was approved after trials revealed favorable response and survival outcomes. MIRV targets folate receptor alpha (FRα), a cell-surface receptor that is overexpressed in EOC and has been associated with aggressive disease phenotypes.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed 425 patient samples tested for FRα using the VENTANA® FOLR1 RxDx immunohistochemical assay. The patient cohort included cases with high grade serous carcinoma predominantly, tested across various anatomical sites. Statistical analysis examined the correlation between FRα positivity and clinical parameters such as tumor site and histology.</div></div><div><h3>Results</h3><div>FRα was highly expressed in 36.3 % of the cases, with a significant association between FRα positivity and high grade serous ovarian histology. Tumor samples from the ovary, fallopian tube, adnexa, and dominant pelvic masses showed higher FRα positivity compared to metastatic sites (positive rates of 44.4 % vs 32.5 %, <em>p</em> = 0.02), highlighting the potential influence of tumor origin on expression of FRα. Time between sample collection and testing did not impact FRα expression, with sample testing spread over a median of 19.5 months post-collection. Eight patients had more than one specimen tested, of which 3 (37.5 %) had discordant results when a subsequent specimen was tested.</div></div><div><h3>Conclusion</h3><div>Our results highlight a need for standardized protocols for FRα testing to ensure accurate biomarker evaluation across varied clinical settings. The heterogeneity in FRα expression, influenced by tumor histology and anatomical origin, warrant further investigation to optimize therapeutic outcomes.</div></div><div><h3>Prior presentation</h3><div>Preliminary findings from this study were previously presented in poster format at the Society of Gynecologic Oncology 2024 Annual Metting. We confirm that the submission complies with the journal requirements.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"192 ","pages":"Pages 102-110"},"PeriodicalIF":4.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0090825824012162","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Epithelial ovarian cancer (EOC) remains a significant challenge in gynecologic oncology, particularly in the context of platinum-resistant disease. Mirvetuximab soravtansine (MIRV), was approved after trials revealed favorable response and survival outcomes. MIRV targets folate receptor alpha (FRα), a cell-surface receptor that is overexpressed in EOC and has been associated with aggressive disease phenotypes.

Methods

This retrospective study analyzed 425 patient samples tested for FRα using the VENTANA® FOLR1 RxDx immunohistochemical assay. The patient cohort included cases with high grade serous carcinoma predominantly, tested across various anatomical sites. Statistical analysis examined the correlation between FRα positivity and clinical parameters such as tumor site and histology.

Results

FRα was highly expressed in 36.3 % of the cases, with a significant association between FRα positivity and high grade serous ovarian histology. Tumor samples from the ovary, fallopian tube, adnexa, and dominant pelvic masses showed higher FRα positivity compared to metastatic sites (positive rates of 44.4 % vs 32.5 %, p = 0.02), highlighting the potential influence of tumor origin on expression of FRα. Time between sample collection and testing did not impact FRα expression, with sample testing spread over a median of 19.5 months post-collection. Eight patients had more than one specimen tested, of which 3 (37.5 %) had discordant results when a subsequent specimen was tested.

Conclusion

Our results highlight a need for standardized protocols for FRα testing to ensure accurate biomarker evaluation across varied clinical settings. The heterogeneity in FRα expression, influenced by tumor histology and anatomical origin, warrant further investigation to optimize therapeutic outcomes.

Prior presentation

Preliminary findings from this study were previously presented in poster format at the Society of Gynecologic Oncology 2024 Annual Metting. We confirm that the submission complies with the journal requirements.

Abstract Image

查看原文本刊更多论文

卵巢癌、输卵管癌和原发性腹膜癌中真实世界FRα检测的分析。

背景：上皮性卵巢癌（EOC）仍然是妇科肿瘤学的一个重大挑战，特别是在铂耐药疾病的背景下。Mirvetuximab soravtansine （MIRV）在试验显示良好的反应和生存结果后被批准。MIRV靶向叶酸受体α (FRα)，这是一种在EOC中过表达的细胞表面受体，与侵袭性疾病表型相关。方法：本回顾性研究分析了425例使用VENTANA®FOLR1 RxDx免疫组织化学法检测FRα的患者样本。患者队列主要包括高级别浆液性癌，在不同解剖部位进行了测试。统计学分析FRα阳性与肿瘤部位、组织学等临床参数的相关性。结果：FRα在36.3%的病例中高表达，FRα阳性与高分级浆液卵巢组织学有显著相关性。与转移部位相比，卵巢、输卵管、附件和优势盆腔肿块的肿瘤样本显示更高的FRα阳性（阳性率为44.4%对32.5%,p = 0.02），突出了肿瘤来源对FRα表达的潜在影响。样本收集和检测之间的时间不影响FRα表达，样本收集后的中位数为19.5个月。8例患者检测了不止一个标本，其中3例（37.5%）在随后的标本检测时结果不一致。结论：我们的研究结果强调需要标准化的FRα检测方案，以确保在不同的临床环境中准确评估生物标志物。FRα表达的异质性受肿瘤组织学和解剖学起源的影响，值得进一步研究以优化治疗效果。先前报告：本研究的初步结果先前以海报形式在妇科肿瘤学会2024年年会上发表。我们确认投稿符合期刊要求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy